Drugs / Dalpicilib
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT06500247 | Jul 2024 → Mar 2027 expected | — | Qilu Hospital of Shandong University | Not yet recruiting | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT06637150 | Sep 2024 → Sep 2030 expected | breast cancer | Fudan University | Active not recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Dalpicilib | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06500247 ↗ |
| Route | Oral | “oral administration” NCT06500247 ↗ |